UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of Earliest Event Reported): |
|
August 21, 2007 |
Inovio Biomedical Corporation
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-14888 |
|
33-0969592 |
|
(State or other jurisdiction |
|
(Commission |
|
(I.R.S. Employer |
|
of incorporation) |
|
File Number) |
|
Identification No.) |
|
|
|
|
|
|
|
11494
Sorrento Valley Road, San |
|
|
|
92121-1318 |
|
(Address of
principal executive |
|
|
|
(Zip Code) |
|
Registrant’s telephone number, including area code: |
|
(858) 597-6006 |
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 21, 2007, Inovio Biomedical Corporation (the “registrant” or “Inovio”) promoted to Michael Fons, PhD, MBA, to from Executive Director of Corporate Development to Vice President of Corporate Development.
Dr. Fons, 48, joined Inovio as Executive Director of Corporate Development in June 2004. In such capacity, he has been instrumental in defining Inovio’s corporate strategy relating to DNA vaccines and DNA delivery, including assisting in securing DNA-related license agreements, acquiring valuable intellectual property assets, and establishing a strong standard for the management of Inovio’s corporate relationships. Prior to joining Inovio, Mr. Fons held business development roles with Vical (March 2002 – May 2004), GeneMedicine (November 1993 – January 2002), and Valentis. He is an Adjunct Associate Professor of Microbiology and Immunology with the University of Texas Medical Branch. Dr. Fons is a published author of 24 papers in scientific journals and numerous book chapters.
Inovio plans to enter into an employment agreement with Dr. Fons for his service as Vice President of Corporate Development.
Dr. Fons is not related by blood, marriage or adoption to any of the registrant’s executive officers or directors, nor has Dr. Fons been party to any transaction requiring disclosure pursuant to Item 404(a) of Regulation S-K.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
|
99.1 |
|
Press release dated August 21, 2007 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 24, 2007
|
INOVIO BIOMEDICAL CORPORATION |
|||
|
|
|
||
|
|
|
||
|
|
By: |
/s/ Peter Kies |
|
|
|
Peter Kies, Chief Financial Officer |
||
3